Home > Signaling Pathways>Anti-infection>Parasite>Tafenoquine
Tafenoquine

This product is for research use only, not for human use. We do not sell to patients.

Tafenoquine
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
250mg$950Check With Us
500mg$1650Check With Us
1g$2475Check With Us
email: [email protected]        [email protected]

Cat #: V3882 CAS #: 106635-80-7 Purity ≥ 98%

Description: Tafenoquine (formerly known as SB252263-AAB; WR-238605; WR238605; Brand name Krintafel) is an 8-aminoquinoline analog and oral drug developed by GlaxoSmithKline that has been investigated and approved in 2018 as a potential treatment for malaria, as well as for malaria prevention. In July 2018, United States Food and Drug Administration (US FDA) approved single dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax malaria. Tafenoquine targets leishmania respiratory complex III and induces apoptosis. Tafenoquine has a long half-life of approximately 14 days and is generally safe and well tolerated.

References: Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)463.50
Molecular FormulaC24H28F3N3O3
CAS No.106635-80-7
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 10 mMr
Water: N/Ar
Ethanol: N/A
SMILES CodeCC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
SynonymsWR-238605, SB252263-AAB; WR 238605, SB-252263-AAB; WR238605; SB 252263-AAB
ProtocolIn VitroEravacycline is potent antibiotic against A. baumannii, including isolates that are resistant to sulbactam, SM 7338, and BAY 41-6551. Eravacycline shows greater activity than BAY 41-6551, and colistin. The eravacycline MIC50/90 values are 0.5/1 mg/L.
In VivoMice are treated with two-fold increasing doses (range 3.125 to 50 mg/kg) of eravacycline every 12 hours. The mean fAUC/MIC magnitude associated with net stasis and 1-log kill endpoint are 27.97 ± 8.29 and 32.60 ± 10.85, respectively.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.1575 mL10.7875 mL21.5750 mL43.1499 mL
5mM0.4315 mL2.1575 mL4.3150 mL8.6300 mL
10mM0.2157 mL1.0787 mL2.1575 mL4.3150 mL
20mM0.1079 mL0.5394 mL1.0787 mL2.1575 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.